GPLGIAGQ, a MMP2-cleavable polypeptide, is used as a stimulus-sensitive linker in both liposomal and micellar nanocarriers for MMP2-triggered tumor targeting.
CAT No: 10-101-303
CAS No: 109053-09-0
Chemical Name: (2S)-5-amino-2-[[2-[[(2S)-2-[[(2S,3S)-2-[[2-[[(2S)-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-methylpentanoyl]amino]propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
Quick InquiryCustom Peptide SynthesisRegistration of APIs CMC information required for an IND
IND and NDA support Drug master files (DMF) filing
Synonyms/Alias | GPLGIAGQ;109053-09-0;L-Glutamine, glycyl-L-prolyl-L-leucylglycyl-L-isoleucyl-L-alanylglycyl-;(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S,3S)-2-[[2-[[(2S)-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-methylpentanoyl]amino]propanoyl]amino]acetyl]amino]-5-oxopentanoic acid;Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln;HY-P2213;DA-73847;CS-0113488;Glycyl-L-prolyl-L-leucylglycyl-L-isoleucyl-L-alanylglycyl-L-glutamine; |
M.F/Formula | C31H53N9O10 |
M.W/Mr. | 711.8 |
Sequence | One Letter Code:GPLGIAGQ Three Letter Code:H-Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln-OH |
Purity | ≥97% (HPLC) |
Long-term Storage Conditions | 10 mM in DMSO |
Shipping Condition | +20°C (International: -20°C) |
InChI | InChI=1S/C31H53N9O10/c1-6-17(4)26(30(48)36-18(5)27(45)34-14-23(42)37-19(31(49)50)9-10-22(33)41)39-24(43)15-35-28(46)20(12-16(2)3)38-29(47)21-8-7-11-40(21)25(44)13-32/h16-21,26H,6-15,32H2,1-5H3,(H2,33,41)(H,34,45)(H,35,46)(H,36,48)(H,37,42)(H,38,47)(H,39,43)(H,49,50)/t17-,18-,19-,20-,21-,26-/m0/s1 |
InChI Key | BLNMYSBCIVAVFK-PFZXUFBWSA-N |
Canonical SMILES | CCC(C)C(C(=O)NC(C)C(=O)NCC(=O)NC(CCC(=O)N)C(=O)O)NC(=O)CNC(=O)C(CC(C)C)NC(=O)C1CCCN1C(=O)CN |
Isomeric SMILES | CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)CN |
1. High fat diet and GLP-1 drugs induce pancreatic injury in mice
2. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes
5. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us. We will endeavor to provide highly satisfying products and services.